Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Has Consensus Price Target of $63.50

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has earned a consensus rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $63.50.

A number of research firms have recently weighed in on SUPN. Zacks Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Piper Sandler initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday. They set an “overweight” rating and a $47.00 target price on the stock. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Jefferies Financial Group initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday. They issued a “strong-buy” rating for the company.

Supernus Pharmaceuticals Trading Down 2.2%

NASDAQ:SUPN opened at $26.16 on Friday. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of 7.31, a P/E/G ratio of 1.19 and a beta of 0.52. Supernus Pharmaceuticals has a 12 month low of $25.92 and a 12 month high of $42.81. The company has a 50-day moving average price of $41.02 and a 200-day moving average price of $46.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.14). The business had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 12.99%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company earned ($0.80) EPS. Equities analysts forecast that Supernus Pharmaceuticals will post 3.15 EPS for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The business also recently declared a special dividend, which was paid on Friday, November 6th. Shareholders of record on Friday, October 30th were issued a $8.13 dividend.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SUPN. Mystic Asset Management Inc. acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $1,181,000. Bank of America Corp DE bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at $28,887,000. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at $434,871,000. The Manufacturers Life Insurance Company purchased a new position in Supernus Pharmaceuticals during the second quarter worth approximately $1,298,000. Finally, Great Lakes Advisors LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $1,386,000. 60.33% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.